Phase II Study of Liposomal Doxorubicin in Advanced Gynecologic Cancers

Author： Israel V.P.   Garcia A.A.   Roman L.   Muderspach L.   Burnett A.   Jeffers S.   Muggia F.M.  

Publisher： Elsevier

ISSN： 0090-8258

Source： Gynecologic Oncology, Vol.78, Iss.2, 2000-08, pp. : 143-147

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Mitomycin, Doxorubicin, and Cisplatin in the Treatment of Advanced Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study

By Edmonson J.H.   Blessing J.A.   Cosin J.A.   Miller D.S.   Cohn D.E.   Rotmensch J.  

Gynecologic Oncology, Vol. 85, Iss. 3, 2002-06 ,pp. : 507-510

Academic Press

Access to resources Recommend Favorite

A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer

By Vujaskovic Zeljko   Kim Dong W.   Jones Ellen   Lan Lan   Mccall Linda   Dewhirst Mark W.   Craciunescu Oana   Stauffer Paul   Liotcheva Vlayka   Betof Allison   Blackwell Kimberly  

International Journal of Hyperthermia, Vol. 26, Iss. 5, 2010-08 ,pp. : 514-521

Informa Healthcare

Access to resources Recommend Favorite

Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors

By Campos S.M.   Matulonis U.A.   Penson R.T.   Lee H.   Berkowitz R.S.   Duska L.R.   Fuller A.F.   Wilson K.S.   Puchalski T.A.   Supko J.G.   Seiden M.V.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 610-618

Elsevier

Access to resources Recommend Favorite

A Phase I Trial of Prolonged Oral Etoposide and Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study

By Rose P.G.   Rodriguez M.   Walker J.   Greer B.   Fusco N.   McGuire W.  

Gynecologic Oncology, Vol. 85, Iss. 1, 2002-04 ,pp. : 136-139

Elsevier

Access to resources Recommend Favorite

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL(R)/CAELYX(R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma - a study by the EORTC Soft Tissue and Bone Sarcoma Group

By Judson I.   Radford J.A.   Harris M.   Blay J.-Y.   van Hoesel Q.   le Cesne A.   van Oosterom A.T.   Clemons M.J.   Kamby C.   Hermans C.   Whittaker J.   Donato di Paola E.   Verweij J.   Nielsen S.  

European Journal of Cancer, Vol. 37, Iss. 7, 2001-05 ,pp. : 870-877

Elsevier

Access to resources Recommend Favorite